Uthealth Houston
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1967-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
791
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (678 trials with phase data)• Click on a phase to view related trials
Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device
- Conditions
- Blood Pressure
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 40
- Registration Number
- NCT06719518
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder
- Conditions
- Methamphetamine Use Disorder
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-04-18
- Target Recruit Count
- 20
- Registration Number
- NCT06712446
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
- Conditions
- Acute Kidney Injury
- Interventions
- Drug: Protonix (Pantoprazole) 40 mg q 12 hrs for 3 daysDrug: Pepcid (Famotidine) 20 mg q 12 hrs for 3 days
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 400
- Registration Number
- NCT06706258
- Locations
- 🇺🇸
Memorial Hermann Texas Medical Center, Houston, Texas, United States
APPI-Cost Trial for Perforated Appendicitis
- Conditions
- Perforated Appendicitis
- Interventions
- Drug: PVIDrug: Usual Care
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 346
- Registration Number
- NCT06705842
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
- Conditions
- Bipolar II DisorderDepression, BipolarSuicidality
- Interventions
- Behavioral: Therapeutic Support
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 10
- Registration Number
- NCT06706232
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 159
- Next
News
Genprex Secures Exclusive License for REQORSA Gene Therapy in Glioblastoma Treatment
Genprex has entered into an exclusive patent license agreement with UTHealth Houston for its REQORSA gene therapy to treat glioblastoma, expanding beyond its established lung cancer applications.
First-in-Human Trial Tests Herpes Virus-Based Gene Therapy for Neurogenic Bladder in Spinal Cord Injury Patients
A phase 1b/2a clinical trial has begun testing EG110A, a modified herpes virus vector that delivers botulinum toxin genes to treat neurogenic bladder in spinal cord injury patients.
UTHealth Houston Pioneers Telerehabilitation Trial for Underserved Stroke Patients in Rio Grande Valley
UTHealth Houston researchers launch innovative telerehabilitation trial offering at-home stroke recovery services to uninsured patients in Cameron County, Rio Grande Valley.
Phase 3 Trial Success: GTx-104 Shows Promise in Treating Brain Hemorrhage with Reduced Hypotension Risk
Grace Therapeutics' Phase 3 STRIVE-ON trial of GTx-104, an injectable nimodipine formulation, met its primary endpoint with 19% reduction in clinically significant hypotension compared to oral nimodipine in aSAH patients.
GLP-1 Receptor Agonists Show Promise in Protecting Brain Health
• A new review suggests GLP-1 drugs like semaglutide and tirzepatide may offer neuroprotective benefits beyond weight loss and improved insulin sensitivity. • GLP-1 drugs can balance the neurovascular unit, potentially improving cognitive function by reducing brain inflammation associated with obesity. • Research indicates GLP-1 receptor signaling may enhance neuron growth, increase astrocytes, and reverse inflammation by modulating microglia activity. • Clinical trials are underway to assess the efficacy of semaglutide in treating Alzheimer’s disease, with results from the EVOKE trial expected in 2025.
Minimally Invasive Laser Therapy Shows Promise for Drug-Resistant Epilepsy
A study published in _Annals of Neurology_ highlights the effectiveness of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) for drug-resistant epilepsy caused by periventricular nodular heterotopia (PNVH).
Strategic Collaborations and Novel Therapies Advance Cancer and Brain Injury Treatment
• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.
GLP-1 Agonists Show Promise in Smoking Cessation and Weight Management in Clinical Trials
A clinical trial at UTHealth Houston is investigating GLP-1 agonists for smoking cessation and prevention of post-cessation weight gain.